Tag: PICO strategy
Why Pharma Companies Should Stress-Test Their Market Access Strategy Before EU HTA Submission
Why Pharma Companies Should Stress-Test Their Market Access Strategy Before EU HTA Submission How pre-submission evidence reviews are becoming the next competitive advantage for pharmaceutical and biotech companies in Europe. The pharmaceutical industry has entered a new era of evidence generation. For years, achieving regulatory approval was considered the biggest milestone on the path to…
From Evidence Generation to Market Access: Why Integrated Evidence Planning Is Pharma’s Competitive Advantage Under EU HTA
From Evidence Generation to Market Access: Why Integrated Evidence Planning Is Becoming Pharma’s Competitive Advantage Under EU HTA How cross-functional collaboration, Real-World Evidence, AI, and early planning are reshaping successful market access strategies across Europe. The European pharmaceutical landscape is changing rapidly. Over the past year, discussions around the EU Health Technology Assessment (HTA) Regulation…
What Can We Learn from the First Three EU Joint Clinical Assessment (JCA) Reports?
What Can We Learn from the First Three EU Joint Clinical Assessment (JCA) Reports? The European Union’s Health Technology Assessment (HTA) Regulation has entered a new era. In just a few months, the European Commission has published the first three official Joint Clinical Assessment (JCA) reports, providing pharmaceutical companies with the clearest indication yet of…
Evidence Generation Is No Longer Enough: Why Evidence Prioritisation Is Pharma’s Next Competitive Advantage
Evidence Generation Is No Longer Enough: Why Evidence Prioritisation Is Pharma’s Next Competitive Advantage in the EU HTA Era The Industry Has Moved Beyond Generating More Evidence For years, pharmaceutical innovation has focused on answering one fundamental question: “Do we have enough evidence to secure regulatory approval?” Today, that question has evolved. Across Europe, Market…
Overcoming ‘PICO Anxiety’: How Biopharma Can Master the New European HTA Era
Overcoming ‘PICO Anxiety’: How Biopharma Can Master the New European HTA Era The European pharmaceutical market access landscape is entering a new phase. With the implementation of the European Union Health Technology Assessment (EU HTA) Regulation, Joint Clinical Assessments (JCA) are becoming an integral part of evidence planning for eligible medicines across Europe. As mandatory…
